RVNC Revance Therapeutics
- 4.290
- +0.020+0.47%
- 4.000
- -0.290-6.76%
Revance Therapeutics News
Revance Therapeutics | 10-Q: Quarterly report
Revance Therapeutics Launches DAXXIFY for Cervical Dystonia
Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, Vs. Street Est of $56.7M
04:23 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M
Revance Therapeutics: Continues to Expect 2024 Total Net Pdt Rev, Which Includes Sales of DAXXIFY and the RHA Collection, to Be at Least $280M >RVNC
Revance Therapeutics: Continues to Expect 2024 Total Net Pdt Rev, Which Includes Sales of DAXXIFY and the RHA Collection, to Be at Least $280M >RVNC
Press Release: Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update - Total net product revenue (DAXXIFY(R) and RHA(R) Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY(R) n
Revance Therapeutics Q1 2024 GAAP EPS $(0.54) Beats $(0.63) Estimate, Sales $51.936M Miss $56.634M Estimate
Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.63) by 14.29 percent. The company reported quarterly sales of $51.936
Revance Therapeutics 1Q Rev $51.9M >RVNC
Revance Therapeutics 1Q Rev $51.9M >RVNC
Revance Therapeutics (RVNC) Receives a Buy From Barclays
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9,
Barclays Sticks to Their Buy Rating for Revance Therapeutics (RVNC)
OPI, RVNC and AQST Are Among After Hour Movers
AbbVie Working With FDA After Reports of Fake Botox Versions
Revance To Present New DAXXIFY Data At The American Academy Of Neurology 2024 Annual Meeting
– Two presentations highlighting data on DAXXIFY for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract exa
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday.
Take Care Before Jumping Onto Revance Therapeutics, Inc. (NASDAQ:RVNC) Even Though It's 35% Cheaper
To the annoyance of some shareholders, Revance Therapeutics, Inc. (NASDAQ:RVNC) shares are down a considerable 35% in the last month, which continues a horrid run for the company. For any long-term
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units ("RSUs") to 29 employees. The RSUs vest over four years, with 25% of the
Survey Finds GLP-1 Users More Inclined to Get Aesthetic Procedures
Global Cell Penetrating Peptide Market to Reach $8.40 Billion by 2030 Owing To Increasing Demand for Targeted Drug Delivery Systems | Says Coherent Market Insights
BURLINGAME, Calif., March 11, 2024 /PRNewswire/ -- Coherent Market Insights published a report, titled, Global Cell Penetrating Peptide Market, By Type (Protein Derived CPPs, Synthetic CPPs, Chimeric
Revance Stock Rises After CEO Discloses Share Purchase
GDS Holdings, Coinbase And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling by around 100 points on Monday. Shares of GDS Holdings Limited (NASDAQ:GDS) shares rose sharply in today's pre-market trading
Analysis
Price Target
No Data
